ClinicalTrials.gg
RecruitingNCT05272618CMD-MINOCAUpdated May 12, 2026

Coronary Microvascular Dysfunction Assessments in Myocardial Infarction With Non-Obstructive Coronary Arteries

An observational study in Myocardial Infarction, Coronary Microvascular Dysfunction and Vasospasm, Coronary, sponsored by Chonnam National University Hospital. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-05-12.

Primary conditionMINOCARegistry: Myocardial InfarctionReclassifiedWhy we changed it
Registry
Myocardial Infarction — the first condition term the registry derived for this study.
ClinicalTrials.gg
MINOCA
Why
  1. The study's title name MINOCA, a narrower term within Myocardial Infarction.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Chonnam National University Hospital · Observational

From the registry’s dates

  • Started Feb 2022; still recruiting 4 years 8 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
19 Years and older
Sex
All
01

Study summary

To compare clinical outcomes of myocardial infarction with non-obstructive coronary arteries (MINOCA) according to the coronary microvascular dysfunction (CMD), evaluated by optical coherence tomography (OCT), invasive and non-invasive coronary physiologic assessment.

Read the detailed description

Background Approximately 5\~10% of patients with acute myocardial infarction (AMI) have been reported as myocardial infarction with non-obstructive coronary arteries (MINOCA) in the contemporary clinical setting. Although those with MINOCA have a better prognosis than with obstructive coronary artery disease, several observational studies continuously reported that patients with MINOCA showed comparable outcomes. One plausible explanation of this discrepancy is the heterogeneous and variable definition of MINOCA. Possible causes of MINOCA include plaque erosion and/or rupture, vasospasm, and CMD. Therefore, it is natural that heterogeneous pathophysiology of MINOCA causes diagnostic challenges and proper management.

Recently, there have been efforts for establishing the diagnosis of MINOCA and standardizing the systematic management according to the cause of MINOCA. According to the AHA scientific statement, patients who suspected MINOCA have been recommended to perform multimodality approach, including intravascular imaging (i.e., OCT). Although non-invasive methods, such as N-13 ammonia positron emission tomography (PET), can be used for evaluating the CMD, invasive coronary physiologic assessment using pressure-temperature wire has been recommended. CMD has been known as a major cause of MINOCA, and it may be required specific treatment.

Nevertheless, there has no data on the outcomes of MINOCA with or without CMD. Therefore, the aim of CMD-MINOCA sought to assess the MINOCA patients regarding the latest clinical pathway for diagnosis of CMD and evaluate their clinical outcomes at 2 years.

02

Conditions studied

  • Myocardial Infarction
  • Coronary Microvascular Dysfunction
  • Vasospasm, Coronary

Browse trials for

Keywords

  • MINOCA
  • Coronary physiology
  • Cardiac PET
  • CFR
  • IMR
  • OCT
03

In context

MINOCA Reclassified

29 studies on the registry are indexed under MINOCA; 18 are open to participants now.

This study's planned enrollment of 150 is below the median of 500 across 20 observational studies indexed under MINOCA.

Browse MINOCA studies →

Lead sponsor

Chonnam National University Hospital is the lead sponsor of 72 studies on the registry; 15 are open to participants now.

Compared within MINOCA, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Myocardial Infarction. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

About 150 patients with suspected myocardial infarction underwent invasive coronary angiography, but without obstructive coronary arteries will be enrolled. These patients will be evaluated by OCT, coronary functional assessment including coronary spasm test, invasive (FFR, CFR, IMR) and non-invasive coronary physiologic assessment (N-13 ammonia positron emission tomography).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject with age ≥19 years and acute myocardial infarction

    • Rise and/or fall of cardiac troponin with one level >99 percentile plus ischemic signs/symptoms

      • Subject with non-obstructive coronary arteries
    • \<50% diameter stenosis or
    • fractional flow reserve (FFR) >0.80 ③ Subject without previous history of coronary artery disease

      • Subject who performed invasive coronary angiography within 24 hours after presentation ⑤ Subject who eligible for invasive and non-invasive coronary physiologic assessment

Exclusion criteria

Exclusion Criteria:

  • Subject with obstructive coronary arteries

    • Subject with alternate diagnosis including sepsis, pulmonary embolism, myocarditis, Takotsubo syndrome, spontaneous coronary dissection, and other cardiomyopathies.

      • Subject with cardiogenic shock or cardiac arrest ④ Subject who has non-cardiac co-morbid conditions with \<1 year ⑤ Subject or lactating women ⑥ Subject unable to provide consent
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • MINOCA with CMD

    MINOCA patients with CMD proven by invasive or non-invasive method

    Diagnostic Test: Intravascular imaging (OCT), Invasive physiologic assessment (FFR, CFR, IMR), or Non-invasive physiologic assessment (N-13 ammonia PET)

  • MINOCA without CMD

    MINOCA patients without CMD

    Diagnostic Test: Intravascular imaging (OCT), Invasive physiologic assessment (FFR, CFR, IMR), or Non-invasive physiologic assessment (N-13 ammonia PET)

Interventions

  • Diagnostic testIntravascular imaging (OCT), Invasive physiologic assessment (FFR, CFR, IMR), or Non-invasive physiologic assessment (N-13 ammonia PET)

    Intravascular imaging (OCT), Invasive physiologic assessment (FFR, CFR, IMR), or Non-invasive physiologic assessment (N-13 ammonia PET)

06

What researchers measure

Primary outcomes

  1. MACCE

    a composite of cardiac death, any MI, any revascularization, stroke, readmission due to heart failure

    Time frame: 2-Year after enrollment

Secondary outcomes

  1. cardiac death

    death from cardiac-cause

    Time frame: 2-Year after enrollment

  2. all-cause death

    death from any-cause

    Time frame: 2-Year after enrollment

  3. Rate of myocardial infarction

    any type of myocardial infarction

    Time frame: 2-Year after enrollment

  4. Rate of repeat revascularization

    ischemia-driven or all

    Time frame: 2-Year after enrollment

  5. Rate of stroke

    ischemic or hemorrhagic stroke by brain imaging

    Time frame: 2-Year after enrollment

  6. re-admission due to heart failure

    re-admission due to heart failure

    Time frame: 2-Year after enrollment

  7. all-cause death, any MI, or any revascularization

    a composite of all-cause death, any myocardial infarction, or any revascularization

    Time frame: 2-Year after enrollment

  8. Changes of left ventricular ejection fraction

    left ventricular ejection fraction by echocardiography

    Time frame: 2-Year after enrollment

  9. Changes of Coronary flow reserve

    Coronary flow reserve by PET

    Time frame: 6-Month after enrollment

07

Study locations

1 of 1 sites recruiting
  • Chonnam National University Hospital
    Gwangju, Gwangju 61469, South Korea
    Recruiting
    • Young Joon Hong, MD, PhD · Contacthyj200@hanmail.net · 82-10-2055-7919
    • Seung Hun Lee, MD, PhD · Contactlsh8602@naver.com · 82-10-6413-7449
    • Young Joon Hong, MD, PhD · Principal investigator
    • Seung Hun Lee, MD, PhD · Sub investigator
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — After the publication of the main paper, we have a plan to share IPD regarding the request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: December 31, 2026 \~

Access criteria: Not specified. To be discussed.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05272618
Lead sponsor
Chonnam National University Hospital
Collaborators
Korean Cardiac Research Foundation, Abbott
Responsible party
Young Joon Hong (Professor, Chonnam National University Hospital) — Principal investigator
First posted
Mar 9, 2022
Start date
Feb 14, 2022
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
May 12, 2026

Study contacts

Young Joon Hong, MD, PhD
Contact
hyj200@hanmail.net
82-10-2055-7919
Seung Hun Lee, MD, PhD
Contact
lsh8602@naver.com
82-10-6413-7449
Young Joon Hong, MD, PhD
principal investigator · Chonnam National University Medical School; Chonnam National University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion